リラグルチドとセマグルチドの世界市場レポート 2025年

リラグルチドとセマグルチド市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.5％で262億4,000万米ドルに成長します。予測期間の成長は、GLP-1受容体作動薬の採用増加、ヘルスケア支出の増加、製薬会社の製品ポートフォリオの拡大、可処分所得の増加、糖尿病に罹患しやすい老年人口の増加などに起因すると考えられます。予測期間における主な動向としては、デジタルヘルスプラットフォームの統合、個別化投与戦略の導入、ドラッグデリバリー技術の進歩、バイオシミラー医薬品の開発、治療意思決定における人工知能の統合などが挙げられます。

糖尿病患者の増加は、今後のリラグルチドとセマグルチド市場の成長を牽引すると予想されます。糖尿病は、インスリン抵抗性とインスリン分泌不足による血糖値の上昇を特徴とする慢性疾患です。糖尿病の有病率の増加は、座りがちなライフスタイル、食生活の乱れ、遺伝的素因などの要因に起因しています。リラグルチドとセマグルチドは、血糖値をコントロールし、関連する合併症のリスクを軽減することで、糖尿病の管理に重要な役割を果たしています。例えば、2024年6月、英国の政府部門である国民保健サービス（NHS）は、2023年にイングランドで新たに50万人以上が2型糖尿病を発症するリスクがあると確認されたと報告しました。これにより、GPに登録された糖尿病予備軍（非糖尿病性高血糖）の総数は361万5,330人となり、306万5,825人だった2022年から20％近く増加しました。このように、糖尿病患者数の増加がリラグルチドとセマグルチド市場の成長を牽引しています。

リラグルチドとセマグルチド市場の主要企業は、患者の血糖管理を改善し心血管リスクを低下させるために、抗糖尿病バイオシミラー医薬品を開発しています。これらのバイオシミラー医薬品は、糖尿病治療薬の先発品とほぼ同じもので、先発品と同じ健康上の利点を提供するように設計されています。例えば、2024年1月、インドに本社を置くグレンマーク・ファーマシューティカルズ社は、広く使用されている抗糖尿病薬リラグルチドのバイオシミラーをインドで発売しました。この新しいバイオシミラーは、成人の2型糖尿病患者の血糖コントロールを強化することを目的としており、1日の治療費を約70％大幅に削減し、標準的な1.2mgの投与量は100インドルピー程度であるため、全国的に治療がより身近なものとなっています。購入には処方箋が必要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界リラグルチドとセマグルチド PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のリラグルチドとセマグルチド市場：成長率分析
• 世界のリラグルチドとセマグルチド市場の実績：規模と成長, 2019-2024
• 世界のリラグルチドとセマグルチド市場の予測：規模と成長, 2024-2029, 2034F
• 世界リラグルチドとセマグルチド総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のリラグルチドとセマグルチド市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• 液体
• 世界のリラグルチドとセマグルチド市場管理局による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口
• オーラル
• 世界のリラグルチドとセマグルチド市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2型糖尿病
• 肥満
• その他の用途
• 世界のリラグルチドとセマグルチド市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のリラグルチドとセマグルチド市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口錠（リラグルチド、セマグルチド）
• 徐放性経口製剤
• 世界のリラグルチドとセマグルチド市場、液体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射液（リラグルチド、セマグルチド）
• プレフィルドシリンジ
• 注射用バイアル

第7章 地域別・国別分析

• 世界のリラグルチドとセマグルチド市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のリラグルチドとセマグルチド市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• リラグルチドとセマグルチド市場：競合情勢
• リラグルチドとセマグルチド市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Otsuka Holdings Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Sumitomo Pharma Co. Ltd.
• Shionogi & Co. Ltd.
• Cadila Pharmaceuticals
• Kyowa Kirin Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Biocon
• Glenmark Pharmaceuticals Ltd.
• Bachem
• Zealand Pharma
• Shenzhen JYMed Technology Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• リラグルチドとセマグルチド市場2029：新たな機会を提供する国
• リラグルチドとセマグルチド市場2029：新たな機会を提供するセグメント
• リラグルチドとセマグルチド市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Liraglutide and semaglutide are medications classified as glucagon-like peptide-1 (GLP-1) receptor agonists. They are primarily used to manage type 2 diabetes mellitus and help improve glycemic control in adults with this condition. These injectable medications are generally prescribed when other diabetes or obesity treatments have proven insufficient. They are often included in a comprehensive treatment plan that may also involve diet, exercise, and additional medications as needed.

Liraglutide and semaglutide are available in two main forms pills and liquids. Pills are solid-form medications usually taken orally to treat conditions such as type 2 diabetes mellitus and obesity. The medications can be administered in various ways, including parenteral and oral methods, depending on the application. They are distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The liraglutide and semaglutide market research report is one of a series of new reports from The Business Research Company that provides liraglutide and semaglutide market statistics, including liraglutide and semaglutide industry global market size, regional shares, competitors with a liraglutide and semaglutide market share, detailed liraglutide and semaglutide market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide and semaglutide industry. This liraglutide and semaglutide market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The liraglutide and semaglutide market size has grown rapidly in recent years. It will grow from $15.19 billion in 2024 to $16.98 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the increasing prevalence of diabetes, growing incidence of obesity-related diseases, growth in the number of clinical trials, growing investment in diabetes research and development, and rising demand for convenient treatment options.

The liraglutide and semaglutide market size is expected to see rapid growth in the next few years. It will grow to $26.24 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising adoption of GLP-1 receptor agonists, increasing healthcare expenditure, expansion of pharmaceutical company product portfolios, rising disposable incomes, rising geriatric population susceptible to diabetes. Major trends in the forecast period include the integration of digital health platforms, implementation of personalized dosing strategies, advancements in drug delivery technologies, development of biosimilar versions, and integration of artificial intelligence in treatment decision-making.

The growing number of diabetic patients is expected to drive the growth of the liraglutide and semaglutide markets in the future. Diabetes is a chronic condition marked by elevated blood sugar levels due to insulin resistance and insufficient insulin production. The increasing prevalence of diabetes can be attributed to factors such as sedentary lifestyles, poor dietary habits, and genetic predispositions. Liraglutide and semaglutide play a crucial role in managing diabetes by helping control blood glucose levels and reducing the risk of related complications. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that in 2023, over half a million additional individuals in England were identified as being at risk of developing type 2 diabetes. This brought the total number of people with pre-diabetes, or non-diabetic hyperglycemia, registered with a GP to 3,615,330, marking a nearly 20% increase from 2022, when the number was 3,065,825. Thus, the rising number of diabetic patients is driving the growth of the liraglutide and semaglutide markets.

Leading companies in the liraglutide and semaglutide markets are creating anti-diabetic biosimilar drugs to improve glucose management and lower cardiovascular risks for patients. These biosimilars are affordable, nearly identical replicas of original diabetes biologics, designed to offer the same health benefits as the original medications. For example, in January 2024, Glenmark Pharmaceuticals Ltd., based in India, introduced a biosimilar of the widely used anti-diabetic drug Liraglutide in India. This new biosimilar, aimed at enhancing glycemic control for adults with type 2 diabetes mellitus, significantly reduces daily therapy costs by about 70%, with a standard 1.2 mg dose priced around INR 100, making treatment more accessible nationwide. Prescription is required for purchase.

In October 2023, Biocon Limited, an Indian biopharmaceutical firm specializing in biosimilar diabetes medications such as liraglutide (Victoza) and semaglutide (Ozempic), formed a partnership with Juno Pharmaceuticals. This collaboration focuses on bringing Liraglutide, a complex drug-device combination for Type 2 diabetes and obesity treatment, to market. The partnership aims to secure regulatory approval, streamline manufacturing, and enhance supply, ultimately improving healthcare access and affordability through innovative solutions. Juno Pharmaceuticals, based in Canada, develops high-value generic medications, complex formulations, and biosimilars.

Major companies operating in the liraglutide and semaglutide market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Cadila Pharmaceuticals, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Biocon, Glenmark Pharmaceuticals Ltd., Bachem, Zealand Pharma, Shenzhen JYMed Technology Co. Ltd., Incepta Pharmaceuticals Ltd.

North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liraglutide and semaglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liraglutide and semaglutide markets consist of sales of medicines such as Victoza, saxenda, ozempic, and rybelsus. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liraglutide And Semaglutide Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liraglutide and semaglutide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liraglutide and semaglutide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liraglutide and semaglutide market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Pills; Liquid
• 2) By Administration: Parenteral; Oral
• 3) By Application: Type 2 Diabetes Mellitus; Obesity; Other Applications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Pills: Oral Tablets (Liraglutide, Semaglutide); Extended-Release Oral Formulations
• 2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide); Pre-Filled Syringes; Vials For Injection
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bristol-Myers Squibb; AstraZeneca; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liraglutide And Semaglutide Market Characteristics

3. Liraglutide And Semaglutide Market Trends And Strategies

4. Liraglutide And Semaglutide Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Liraglutide And Semaglutide Growth Analysis And Strategic Analysis Framework

• 5.1. Global Liraglutide And Semaglutide PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Liraglutide And Semaglutide Market Growth Rate Analysis
• 5.4. Global Liraglutide And Semaglutide Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Liraglutide And Semaglutide Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Liraglutide And Semaglutide Total Addressable Market (TAM)

6. Liraglutide And Semaglutide Market Segmentation

• 6.1. Global Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pills
• Liquid
• 6.2. Global Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• 6.3. Global Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2 Diabetes Mellitus
• Obesity
• Other Applications
• 6.4. Global Liraglutide And Semaglutide Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Liraglutide And Semaglutide Market, Sub-Segmentation Of Pills, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets (Liraglutide, Semaglutide)
• Extended-Release Oral Formulations
• 6.6. Global Liraglutide And Semaglutide Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Solutions (Liraglutide, Semaglutide)
• Pre-Filled Syringes
• Vials For Injection

7. Liraglutide And Semaglutide Market Regional And Country Analysis

• 7.1. Global Liraglutide And Semaglutide Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Liraglutide And Semaglutide Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Liraglutide And Semaglutide Market

• 8.1. Asia-Pacific Liraglutide And Semaglutide Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Liraglutide And Semaglutide Market

• 9.1. China Liraglutide And Semaglutide Market Overview
• 9.2. China Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Liraglutide And Semaglutide Market

• 10.1. India Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Liraglutide And Semaglutide Market

• 11.1. Japan Liraglutide And Semaglutide Market Overview
• 11.2. Japan Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Liraglutide And Semaglutide Market

• 12.1. Australia Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Liraglutide And Semaglutide Market

• 13.1. Indonesia Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Liraglutide And Semaglutide Market

• 14.1. South Korea Liraglutide And Semaglutide Market Overview
• 14.2. South Korea Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Liraglutide And Semaglutide Market

• 15.1. Western Europe Liraglutide And Semaglutide Market Overview
• 15.2. Western Europe Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Liraglutide And Semaglutide Market

• 16.1. UK Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Liraglutide And Semaglutide Market

• 17.1. Germany Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Liraglutide And Semaglutide Market

• 18.1. France Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Liraglutide And Semaglutide Market

• 19.1. Italy Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Liraglutide And Semaglutide Market

• 20.1. Spain Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Liraglutide And Semaglutide Market

• 21.1. Eastern Europe Liraglutide And Semaglutide Market Overview
• 21.2. Eastern Europe Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Liraglutide And Semaglutide Market

• 22.1. Russia Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Liraglutide And Semaglutide Market

• 23.1. North America Liraglutide And Semaglutide Market Overview
• 23.2. North America Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Liraglutide And Semaglutide Market

• 24.1. USA Liraglutide And Semaglutide Market Overview
• 24.2. USA Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Liraglutide And Semaglutide Market

• 25.1. Canada Liraglutide And Semaglutide Market Overview
• 25.2. Canada Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Liraglutide And Semaglutide Market

• 26.1. South America Liraglutide And Semaglutide Market Overview
• 26.2. South America Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Liraglutide And Semaglutide Market

• 27.1. Brazil Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Liraglutide And Semaglutide Market

• 28.1. Middle East Liraglutide And Semaglutide Market Overview
• 28.2. Middle East Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Liraglutide And Semaglutide Market

• 29.1. Africa Liraglutide And Semaglutide Market Overview
• 29.2. Africa Liraglutide And Semaglutide Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Liraglutide And Semaglutide Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Liraglutide And Semaglutide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Liraglutide And Semaglutide Market Competitive Landscape And Company Profiles

• 30.1. Liraglutide And Semaglutide Market Competitive Landscape
• 30.2. Liraglutide And Semaglutide Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Liraglutide And Semaglutide Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim International GmbH
• 31.2. Novo Nordisk A/S
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Otsuka Holdings Co. Ltd.
• 31.5. Sun Pharmaceutical Industries Ltd.
• 31.6. Sumitomo Pharma Co. Ltd.
• 31.7. Shionogi & Co. Ltd.
• 31.8. Cadila Pharmaceuticals
• 31.9. Kyowa Kirin Co. Ltd.
• 31.10. Dr. Reddy's Laboratories Ltd.
• 31.11. Biocon
• 31.12. Glenmark Pharmaceuticals Ltd.
• 31.13. Bachem
• 31.14. Zealand Pharma
• 31.15. Shenzhen JYMed Technology Co. Ltd.

32. Global Liraglutide And Semaglutide Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Liraglutide And Semaglutide Market

34. Recent Developments In The Liraglutide And Semaglutide Market

35. Liraglutide And Semaglutide Market High Potential Countries, Segments and Strategies

• 35.1 Liraglutide And Semaglutide Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Liraglutide And Semaglutide Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Liraglutide And Semaglutide Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer